NCT05337657 - A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

December 12, 2023

Study Completion Date

February 1, 2024

Conditions

Advanced Breast Cancer

Interventions

DRUG

GB491+Letrozole

Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai